Current Report Filing (8-k)
31 December 2022 - 08:02AM
Edgar (US Regulatory)
0001792581false00017925812022-12-232022-12-23
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 23,
2022
KIROMIC BIOPHARMA, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
|
Delaware
|
|
001-39619
|
|
46-4762913
|
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
7707 Fannin, Suite
140
Houston, TX,
77054
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code (832) 968-4888
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
|
|
|
|
☐
|
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
|
|
|
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
|
|
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
|
|
Title of Each Class
|
|
Trading Symbol(s)
|
|
Name of Each Exchange on Which
Registered
|
|
Common Stock, $0.001 par value
|
|
KRBP
|
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
☐
|
Item 5.02.
|
Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.
|
On December 23, 2022, Dan Clark, Chief Financial Officer of Kiromic
BioPharma, Inc. (the “Company”) notified the Company of his
decision to resign from his position at the Company effective
immediately. Mr. Clark’s resignation from the Company did not
relate to any disagreement with the operations, policies or
practices of the Company on any matters.
On December 27, 2022, the Company entered into a separation
agreement (the “Separation Agreement”) with Mr. Clark. The
Separation Agreement provides for a customary general release of
claims. In addition, the Company will pay Mr. Clark (i) his base
salary through December 23, 2022, and (ii) any accrued but unused
paid time off through December 23, 2022.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
Kiromic BioPharma, Inc.
|
|
|
|
|
|
Date: December 30, 2022
|
By:
|
/s/ Pietro Bersani
|
|
|
|
Pietro Bersani
|
|
|
|
Chief Executive Officer
|
Kiromic BioPharma (NASDAQ:KRBP)
Historical Stock Chart
From May 2023 to Jun 2023
Kiromic BioPharma (NASDAQ:KRBP)
Historical Stock Chart
From Jun 2022 to Jun 2023
